SpyGlass Pharma

SGP · NASDAQ

$26.16+$1.56 (+6.34%)TodayMarket closed ·
Prev close $24.60

About SGP

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

Employees
65
Headquarters
Aliso Viejo, California
Listed
Feb 6, 2026
Sector
Health Care
Industry
Pharmaceuticals

SGP key statistics

Market cap
875.00M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
92.01K
Volume
99.39K
Open price
$24.49
High today
$26.67
Low today
$23.28
52 Week high
$32.44
52 Week low
$17.06

SpyGlass Pharma (SGP) at a glance

As of Oct 20, 2026, SpyGlass Pharma (SGP) shares are priced at $26.16, giving the company a market cap of 875.00M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $23.28 and $26.67. The current price is 12.4% above the day's low and 1.9% below its high.

Volume so far is 99.39K shares, in line with the average of 92.01K shares a day.

Over the past year SpyGlass Pharma has ranged from $17.06 to $32.44, and now sits 59% of the way up that range.

SpyGlass Pharma met or beat analyst EPS estimates in 0 of the last 2 quarters. In Q2 FY26 it reported -$0.59 per share against an estimate of -$0.5195.

The average analyst price target is $44.88, 71.6% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $44.88
Low
$37.37
Now
$26.16
High
$65.10

SGP earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 2 quarters.

  1. Q1 FY26: reported -$0.69 per share against an estimate of -$0.5082
  2. Q2 FY26: reported -$0.59 per share against an estimate of -$0.5195

Similar companies

Companies in the same industry as SpyGlass Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.